Purchase this article with an account.
C.–M. Choe, B.–Y. Ahn, H.–S. Oh, S.–P. Hong, S.–C. Lee, O.–W. Kwon; Vascular endothelial growth factor gene polymorphisms in diabetic retinopathy . Invest. Ophthalmol. Vis. Sci. 2004;45(13):3722.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: Recent studies suggest that increased expression of the vascular endothelial growth factor (VEGF) may play a role in the pathogenesis of diabetic complications. The aim of this study was to assess potential association of the VEGF gene polymorphisms with disease expression of retinopathy in patients with diabetes mellitus. Methods: A total of 96 diabetic patients with or without retinopathy were examined. Polymorphisms in the VEGF and VEGF receptor (VEGFR1) genes were detected by a matrix–assisted laser desorption/ionization time of flight mass spectrometry (MALDI–TOF MS)–based SNP scoring assay, termed Restriction Fragment Mass Polymorphism (RFMP), which exploits differences in molecular weights between common allele and rare allele bases of interest. Results:We found that the genotype frequencies of two polymorphisms shown to be completely linked to each other (vf1, vf2) and one polymorphism (vfr1) within 3’–untranslated regions (3’–UTR) of the VEGF and VEGFR1 significantly differed between patients with (n = 57) and without (n = 39) retinopathy: P = 0.018 and P = 0.037, respectively. Logistic regression analysis revealed that the compound T–T genotypes of vf1/vf2 and A genotype of vfr1 are associated with increased risks of developing retinopathy in diabetes patients: OR=2.87, P = 0.030; OR=4.42, P=0.046, respectively. Conclusions: These data implicate the polymorphisms in the 3’–UTR of the VEGF and VEGFR1 genes as risk factors for diabetic retinopathy.
This PDF is available to Subscribers Only